Results 1 to 10 of about 18,416 (181)

Thrombotic Microangiopathy From Peptide Receptor Radionuclide Therapy [PDF]

Kidney International Reports
In 2023, Schäfer et al.6 reported 3 cases of kidney failure after an overexposure to Lu-PSMA (8 to 10 cycles) because of renal-limited thrombotic microangiopathy (TMA). The outcome was poor because all of them had end-stage-kidney disease. However, the diagnostic work-up for TMA was limited (no genetic testing, no bone marrow examination, and no ...
Paul Delalande, Mickael Bobot, Marie Essig, Corinne Simon, Annie-Pierre Jonville-Béra, Christelle Barbet, Bénédicte Sautenet, Valentin Maisons, Thibaut Carsuzaa, Franck Bruyère, Jean-Michel Halimi   +10 more
doaj   +4 more sources

Peptide receptor radionuclide therapy [PDF]

Best Practice & Research Clinical Gastroenterology, 2005
Peptide receptor radionuclide therapy is a new treatment modality for patients with inoperable or metastasised neuroendocrine gastroenteropancreatic tumours.
Esser, J.-P. (Jan-Paul), Jong, M. (Marcel) de, Krenning, E.P. (Eric), Kwekkeboom, D.J. (Dirk Jan), Teunissen, J.J.M. (Jaap), Valkema, R. (Roelf)   +5 more
core   +9 more sources

Peptide Receptor Radionuclide Therapy in Thyroid Cancer

Frontiers in Endocrinology, 2022
The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited.
Sriram Gubbi, Christian A. Koch, Christian A. Koch, Joanna Klubo-Gwiezdzinska   +3 more
doaj   +3 more sources

Peptides in receptor-mediated radiotherapy : from design to the clinical application in cancers. [PDF]

Frontiers in Oncology, 2013
Short peptides can show high affinity for specific receptors overexpressed on tumor cells. Some of these are already used in cancerology as diagnostic tools and others are in clinical trials for therapeutic applications. Therefore, peptides exhibit great
Catherine eLOZZA, Isabelle eTEULON, André ePELEGRIN, Jean-Pierre ePOUGET, Eric eVIVES   +4 more
doaj   +4 more sources

Role of 18F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for 177Lu-DOTATATE peptide receptor radionuclide therapy [PDF]

Frontiers in Medicine
BackgroundNeuroblastoma is the most common extracranial solid tumor in children. Peptide receptor radionuclide therapy (PRRT) is a treatment modality with great potential, however, the predictive indicators for its efficacy remain unclear. The aim of the
Yuxuan Liu, Yingying Sun, Yingying Sun, Di Zuo, Han Wang, Fei Zheng, Jingfu Wang, Xiaorong Sun   +7 more
doaj   +2 more sources

Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy [PDF]

Frontiers in Oncology
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs
Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, Nasrin V. Ghesani, Edward Wolin, Munir V. Ghesani   +5 more
doaj   +2 more sources

Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors [PDF]

Thoracic Surgery Clinics, 2014
No abstract ...
Bodei, Lisa, Cremonesi, Marta, Grana, Chiara M., Kidd, Mark, Modlin, Irvin M., Paganelli, Giovanni, Severi, Stefano   +6 more
core   +4 more sources

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms [PDF]

Endocrine Oncology
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Rodney J Hicks, Michael S Hofman, Aravind S Ravi Kumar, Nirupa Sachithanandan, Javad Saghebi, Michael Michael, Grace Kong   +11 more
doaj   +2 more sources

Peptide Receptor Radionuclide Therapy

The Journal of Clinical Endocrinology & Metabolism, 2022
Abstract The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule
Johannes Hofland, Tessa Brabander, Frederik A Verburg, Richard A Feelders, Wouter W de Herder   +4 more
openaire   +3 more sources

Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series [PDF]

Archive of Oncology, 2012
Background: Peptide Receptor Radionuclide Therapy (PRRT) is novel and efficacious treatment of neuroendocrine tumors (NETs). Methods: Twenty-seven patients (14 females, 13 males, mean age 54.37±11.14 years; range 30-74 years) with progressive ...
Matović Milovan
doaj   +1 more source